Investor Relations

iCo was awarded a Gold Leaf Award as the Early Stage Company of the Year from BIOTECanada and is a Canada's Top 10™ Competition winner.  

iCo trades on the TSX Venture Exchange under the symbol "ICO".

Contacts:

iCo Finance: John Meekison, CFO.  604-602-9414 meekison@icotherapeutics.com

Equicom Group: Michael Moore, Investor Relations 619-467-7067 mmoore@equicomgroup.com

Crescendo Communications, LLC: David Waldman 212-671-1021 ico@crescendo-ir.com

Fact Sheets

Corporate Fact sheet

iCo-007 Fact sheet

iCo-008 Fact sheet

Oral Amphotericin B Delivery System Fact sheet

News Releases

May 29, 2013:
iCo Therapeutics Announces First Quarter 2013 Financial Results
May 24, 2013:
iCo Therapeutics Announces Director Election Results from its Annual General Meeting of Shareholders
May 21, 2013:
iCo Therapeutics Closes $3.4 Million Financing
Copyright 2010 ICO Therapeutics | Disclaimer